cdr

Hot Keywords
Drug Resistance Mechanisms Epigenetic Resistance in Cancer Therapy Biomarkers Pharmacogenetics of Cancer Liquid Biopsy Targeted Cancer Therapy Non-coding RNAs Kinase Inhibitors ABC Transporters

Top
The paper's citation list
No.The paper's citation list
1Platinum compounds: Their continued impact on ovarian cancer treatment. 2019;496:119037 doi: 10.1016/j.ica.2019.119037
2Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives. 2020;21:4579 doi: 10.3390/ijms21134579
3Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status. 2021;12:1749 doi: 10.18632/oncotarget.28047
4Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer. 2020;12:1206 doi: 10.3390/cancers12051206
5Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial. 2021; doi: 10.4143/crt.2020.1381
© 2016-2021 OAE Publishing Inc., except certain content provided by third parties